Approaches to Remyelination Therapies in Multiple Sclerosis
- 28 June 2019
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 21 (7) , 34
Abstract
While there are a growing number of therapies targeting relapse prevention in multiple sclerosis (MS), there are no approved therapies promoting remyelination. Understanding endogenous myelin formation, remyelination strategies, pre-clinical models, and clinical outcomes is essential to the interpretation of current and future clinical trials of remyelinating agents.Keywords
This publication has 95 references indexed in Scilit:
- A culture system to study oligodendrocyte myelination processes using engineered nanofibersNature Methods, 2012
- Oligodendroglia metabolically support axons and contribute to neurodegenerationNature, 2012
- The Immunopathophysiology of Multiple SclerosisNeurologic Clinics, 2011
- Tapping into the glial reservoir: cells committed to remaining uncommittedJournal of Cell Biology, 2010
- Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNSGenes & Development, 2009
- The geometric and spatial constraints of the microenvironment induce oligodendrocyte differentiationProceedings of the National Academy of Sciences, 2008
- Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiencyNature Neuroscience, 2008
- Neuregulin-1/ErbB Signaling Serves Distinct Functions in Myelination of the Peripheral and Central Nervous SystemNeuron, 2008
- MRI in multiple sclerosis: current status and future prospectsThe Lancet Neurology, 2008
- Diffusion tensor imaging: Concepts and applicationsJournal of Magnetic Resonance Imaging, 2001